AlphAIAlphAI — Financial news for AI agents
tradingview.com$ENOV

Enovis 3Q 2026: Revenue $558.73M, EPS $0.06 — 10-Q Summary

Enovis reported 3Q 2026 revenue of $558.73M, up 1.8% YoY, and net income of $3.14M, reversing a prior-year loss. EPS was $0.06. Sales growth in the Reconstructive segment offset declines in Prevention & Recovery, impacted by the Dr. Comfort divestiture. Adjusted EBITDA rose to $103.5M. The company plans to acquire eCential Robotics, pending approvals.

Original reporting
tradingview.com
Published Nov 5, 2026, 11:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Enovis 3Q 2026: Revenue $558.73M, EPS $0.06 — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$ENOVBullishMed
01

Why it matters

The earnings beat and announced eCential Robotics acquisition provide fresh catalysts for the stock.

02

Market read

New earnings data and acquisition news create a short‑term trading opportunity for ENOV.

03

What to watch

Potential impact of tariff benefits may be temporary; currency translation headwinds remain.

Relevance 7/10Novelty 7/10Timing: post-market filing

Background

Enovis filed its 10‑Q for Q3 2026, showing modest revenue growth and a swing to profitability.

Company-level read

Ticker impact

$ENOVBullishHigh confidence
Context

Enovis reported Q3 2026 revenue of $558.73M and EPS of $0.06, a turnaround from a prior-year loss.

Expected impact

likely upward pressure as market prices in earnings beat and eCential acquisition news

Evidence & confidence

First disclosure of quarterly results and a strategic acquisition, both fresh and material.

Market effects

Sector

Improves outlook for medical device and orthopedics sector with higher sales and margin expansion.

Regional

US healthcare equities may see modest gains.

Global

Limited to investors tracking US med‑tech stocks.

Counterpoint

What could challenge this read

If the acquisition integration risks outweigh earnings beat, the stock could face downside.

Key entities

  • company
    Enovis Corp

    Medical device manufacturer reporting Q3 results.

  • company
    eCential Robotics

    Target of Enovis acquisition.

Read at source← All news

StoryEnovis posts Q3 2026 results, lifts full‑year outlook and authorizes $200 million buyback

Also covered by

4 outlets

Related articles

$ENOVMed

Enovis earnings beat by $0.11, revenue topped estimates

Enovis (ENOV) reported Q3 EPS of $0.88, beating estimates by $0.11, with revenue at $558.72M, slightly above expectations. The company guided FY 2026 EPS to $3.52-$3.73 and revenue to $2.32B-$2.35B, both below consensus. ENOV stock is down 8.23% over 3 months and 14.07% over 12 months, with 11 negative EPS revisions in the last 90 days.

investing.com
$ENOVHighAI 8/10

Enovis: Q3 Earnings Snapshot

Enovis Corporation (ENOV) reported Q3 profit of $3.1M, or 6 cents per share, with adjusted earnings of 88 cents per share. Revenue was $558.7M. The company expects full-year earnings of $3.58-$3.79 per share and revenue of $2.32B-$2.35B, according to its earnings release.

finance.yahoo.com
$ENOVHigh

Enovis Announces Third Quarter 2026 Results

Enovis CORP (ENOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Enovis Announces Third Quarter 2026 Results • Third-quarter sales growth of 2% on a reported basis, 5% organic • Third-quarter Reconstructive sales growth of 6% on a reported and organic basis • Raising full-year 2026 guidance for adjusted EBITDA and adjusted EPS • Board of Direc

SEC EDGAR 8-K